On July 1, Tempus AI rose 5.11% in regular trading, trading at $61.42/share, with turnover of $169 million. The stock extended its upward trend amid continued strength in the AI healthcare sector and a confluence of company-specific catalysts.

On the news front, Tempus AI recently announced a collaboration with Angiosarcoma on rare cancer research, further expanding its precision medicine footprint. Meanwhile, the broader AI healthcare sector continued to rally as capital rotated from speculative plays toward companies with demonstrated clinical deployment capabilities. Tempus AI previously secured FDA approval for tumor-only use of its xT CDx next-generation sequencing platform, making it the first laboratory with FDA companion diagnostic approval for both tumor-only and tumor-normal genomic profiling, with an estimated $200 increase in average selling price expected starting in 2027. The company also expanded its strategic partnership with Bristol-Myers Squibb across five initial clinical trial programs in solid tumor oncology, and launched Lens, a next-generation agentic AI platform for oncology drug development designed to optimize clinical trial design and accelerate evidence generation.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)